Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Non-Invasive Urine Test for Bladder Cancer Could Eliminate Need for Painful Cystoscopy

By LabMedica International staff writers
Posted on 09 Oct 2023

Blood in the urine, or hematuria, is the most common symptom of bladder cancer. More...

However, many patients with microscopic amounts of blood in their urine don't actually have bladder cancer, yet they must undergo invasive tests like cystoscopy to rule it out. Other confirmatory methods like CT scans, intravenous pyelograms, X-rays, MRIs, ultrasounds, and urine cytology also have their limitations. Now, a non-invasive urine test with high sensitivity and negative predicted value (NPV) can help exclude these patients from undergoing unnecessary invasive cystoscopy procedures, thereby streamlining the diagnostic process.

KDx Diagnostics (Los Gatos, CA, USA) has developed the URO17 test, a non-invasive urine test with remarkable sensitivity and NPV for determining active bladder cancer and enhancing patient diagnosis. This test is based on a unique biomarker, Keratin 17 (K17), and is among the most accurate urine tests for bladder cancer. The test uses immunocytochemistry and is compatible with the majority of autostainer platforms commonly found in reference labs. Preliminary research indicates that the URO17 test has a 100% sensitivity and 96% specificity rate for identifying recurring bladder cancers and a 100% sensitivity and 92.6% specificity rate for identifying new cases of bladder cancer in patients with hematuria.

Currently, the URO17 test is available in the United States as a Laboratory Developed Test (LDT) through select reference laboratories and is sold as a CE-IVD kit outside the U.S. The test has received the Breakthrough Device Designation from the FDA and is currently in clinical trials for FDA approval. KDx Diagnostics aims to create additional tests based on the K17 biomarker for various platforms and sample types and plans to expand its range of cancer diagnostic tests. The company has obtained important patents in the U.S., the European Union, and South Korea for technologies that analyze K17 in urine to detect or rule out bladder cancer.

"These new patents complement our ongoing commercial efforts to provide non-invasive technologies for bladder cancer detection and demonstrate we've made groundbreaking advances," said Nam W. Kim, PhD, CEO and CTO at KDx, and coinventor of the patents. "We are focused on delivering cutting-edge solutions that address the needs of our customers and drive industry growth."

Related Links:
KDx Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.